Volume 4.08 | Mar 5

Hematopoiesis News 4.08 March 5, 2013
Hematopoiesis News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Quantitative Assessment of T Cell Repertoire Recovery after Hematopoietic Stem Cell Transplantation
Researchers combined 5′ rapid amplification of complementary DNA ends PCR with deep sequencing to quantify T cell receptor (TCR) diversity in 28 recipients of allogeneic hematopoietic stem cell transplantation using a single oligonucleotide pair. After 6 months, cord blood-graft recipients approximated the TCR diversity of healthy individuals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4+ and CD8+ T cell diversities, respectively. After 12 months, these deficiencies had improved for the CD4+ but not the CD8+ T cell compartment. [Nat Med] Abstract

STEMvision(TM) Instrument
PUBLICATIONS (Ranked by impact factor of the journal)


Control of Hematopoietic Stem Cell Emergence by Antagonistic Functions of Ribosomal Protein Paralogs
The authors demonstrated that despite ubiquitous expression, the ribosomal protein paralogs, Rpl22 and Rpl22-like1 play essential, distinct, and antagonistic roles in hematopoietic development. Knockdown of Rpl22 in zebrafish embryos selectively blocks the development of T lineage progenitors after they have seeded the thymus. [Dev Cell] Abstract | Graphical Abstract | Press Release

TGFβ Restores Hematopoietic Homeostasis after Myelosuppressive Chemotherapy
Scientists showed that TGFβ signaling is transiently activated in hematopoietic stem and progenitor cells during hematopoietic regeneration. Blockade of TGFβ signaling after chemotherapy accelerates hematopoietic reconstitution and delays the return of cycling hematopoietic stem cells to quiescence. [J Exp Med] Abstract

Blockade of Individual Notch Ligands and Receptors Controls Graft-versus-Host Disease
Using newly developed humanized antibodies and conditional genetic models, researchers demonstrated that Notch1/Notch2 receptors and the Notch ligands Delta-like1/4 mediate all the effects of Notch signaling in T cells during graft-versus-host disease, with dominant roles for Notch1 and Delta-like4. [J Clin Invest]
Full Article | Press Release

Erk1 and Erk2 Are Required for Maintenance of Hematopoietic Stem Cells and Adult Hematopoiesis
Extracellular signal-regulated kinase 1 (Erk1) and Erk2 play crucial roles in cell survival, proliferation, cell adhesion, migration, and differentiation in many tissues. The authors report that the absence of Erk1 and Erk2 in murine hematopoietic cells leads to bone marrow aplasia, leukopenia, anemia and early lethality. [Blood] Abstract

Generation of Multi-Leukemia Antigen-Specific T Cells to Enhance the Graft-versus-Leukemia Effect after Allogeneic Stem Cell Transplant
Scientists explored the feasibility of generating tumor associated antigens-specific cytotoxic T lymphocytes from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. [Leukemia] Abstract

Hematopoietic Cells Produce BDNF and Regulate Appetite upon Migration to the Hypothalamus
Scientists showed that brain-derived neurotrophic factor-producing hematopoietic cells control appetite and energy balance by migrating to the hypothalamic paraventricular nucleus. These hematopoietic-derived paraventricular nucleus cells produce microglial markers and make direct contacts with neurons in response to feeding status. [Nat Commun] Abstract | Press Release

Eupalinilide E Inhibits Erythropoiesis and Promotes the Expansion of Hematopoietic Progenitor Cells
The authors performed an unbiased screen using primary human CD34+ hematopoietic stem and progenitor cells (HSPCs) to identify natural products that selectively control their differentiation. They identified a plant-derived natural product, eupalinilide E, that promotes the ex-vivo expansion of HSPCs and hinders the in vitro development of erythrocytes. [ACS Chem Biol] Abstract


Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
HLA-A*0201-restricted Wilms tumor antigen 1 (WT1)-specific donor-derived CD8+ cytotoxic T cell clones were administered after hematopoietic cell transplantation to 11 relapsed or high-risk leukemia patients without evidence of on-target toxicity. [Sci Transl Med] Abstract | Press Release

Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy
Researchers evaluated the clinical implications of CD33 single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-based therapy. [Clin Cancer Res]
Abstract | Press Release

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors

Myocyte Enhancer Factor 2C in Hematopoiesis and Leukemia
High myocyte enhancer factor 2C (MEF2C) expression has been linked to mixed lineage leukemia-rearranged acute myeloid leukemia as well as to the immature subgroup of T-cell acute lymphoblastic leukemia. This review focuses on the role of MEF2C in the hematopoietic system and on aberrant MEF2C expression in human leukemia. [Oncogene] Abstract

Quest for Cures: The Leukemia & Lymphoma Society Seeks to Fund Three Critical Areas of Blood Cancer Research
Medical innovation and sustained research investment are dramatically transforming the landscape in blood cancers. To that end, The Leukemia & Lymphoma Society (LLS) continues to drive a progressive research agenda to improve outcomes for patients who urgently need new therapies. LLS announced it has identified three priority areas toward which it will direct new funding. [The Leukemia & Lymphoma Society]
Press Release

Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation
Targeted Medical Pharma, Inc. unveiled new results from an open label study of its oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia. The company’s ESS system is designed to stimulate progenitor stem cells in the bone marrow. [Targeted Medical Pharma, Inc.]
Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW British Society for Haematology: 53rd Annual Scientific Meeting
April 15-17th, 2013
Liverpool, United Kingdom

Visit our events page to see a complete list of events in the hematopoietic community.


Postdoctoral Position – Hematopoietic and Malignant Stem Cells (Istanbul University)

Postdoctoral Position – Stem Cell Biology (Washington University of Medicine)

Postdoctoral Position – Stem Cell Research (University of Washington)

PhD Studentship (University Medical Center Groningen)

PhD Studentship – Hematopoietic Development and Bioinformatics (Karolinska Institute, Department of Laboratory Medicine)

Postdoctoral Position – Hematopoietic Stem Cells and Stem Cell Aging (Cincinnati Children’s Hospital Research Foundation)

Lecturer or Reader – Associate Professor (University of Reading)

Research Assistant – Stem Cell & Leukemia Epigenetics (King’s College London)

Postdoctoral Position – Bioinformatics and Stem Cell Biology (University of Texas at Houston)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Cord Blood Laboratory Manager (Puget Sound Blood Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada